Defense Advanced Research Projects Agency ("DARPA") Funds George Washington University: Protea Biosciences; SRI International; and GE Global Research Are Partners

Up to $14.6 Million to the George Washington University Team to Develop Rapid Technology for Threat Assessment

Print
| Source: Protea Biosciences, Inc.

MORGANTOWN, W.Va., Jan. 28, 2014 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. ("Protea"), announced today that it is a part of a team led by the George Washington University (GWU) that has been awarded up to $14.6 million for a cooperative agreement spanning five years from the Defense Advanced Research Projects Agency (DARPA). In addition to Protea, SRI International and GE Global Research will collaborate with GWU on this project titled "New Tools for Comparative Systems Biology of Threat Agent Action Mechanisms".

The goal of DARPA's Rapid Threat Assessment (RTA) program is to develop new tools and methods to elucidate the mechanism of action of a threat agent, drug, biologic or chemical on living cells within 30 days from exposure. Uncovering the mechanism of action of such agents in 30 days, compared to the years or decades currently required, could be the key to the development of threat mitigations and countermeasures. Such a new approach could also reduce the strategic advantage associated with rapidly emerging chemical or biological threats in a national security context. 

To achieve this shortened timeline, researchers will seek to develop new methods, based upon technologies invented in the GWU laboratory of Prof. Akos Vertes and exclusively licensed to Protea. Furthermore, GWU and its team will focus on developing de novo molecular network discovery capabilities, as the molecular networks within living cells are vast and complex. Conventional approaches fail to capture the system-wide response of a living cell to a threat agent.

Protea Biosciences Group, Inc.

Protea is a molecular information company, whose proprietary technology enables direct molecular imaging – the ability to identify and display biomolecules in tissue and cells, without sample pretreatment. Protea delivers robust molecular information to medical and life science researchers worldwide.

Protea: https://proteabio.com

Forward-Looking Statements

This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further information concerning the Company and its business, including factors that potentially could materially affect the Company's financial results, are contained in the Company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.

For more Information:
Protea Biosciences Group, Inc.,
955 Hartman Run Road, Morgantown, WV 26507 USA
Phone: 304.292.2226
Fax: 304.292.7101
Stephen.turner@proteabio.com